BioVaxys Technology (FRA:5LB) COGS-to-Revenue : 0.00 (As of Jan. 2025)

View and export this data going back to 2020. Start your Free Trial

What is BioVaxys Technology COGS-to-Revenue?

BioVaxys Technology's Cost of Goods Sold for the three months ended in Jan. 2025 was €0.00 Mil. Its Revenue for the three months ended in Jan. 2025 was €0.00 Mil.

BioVaxys Technology's COGS to Revenue for the three months ended in Jan. 2025 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. BioVaxys Technology's Gross Margin % for the three months ended in Jan. 2025 was N/A%.

BioVaxys Technology COGS-to-Revenue Historical Data

The historical data trend for BioVaxys Technology's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology COGS-to-Revenue Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

COGS-to-Revenue

Get a 7-Day Free Trial

BioVaxys Technology Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

BioVaxys Technology COGS-to-Revenue Calculation

BioVaxys Technology's COGS to Revenue for the fiscal year that ended in Oct. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

BioVaxys Technology's COGS to Revenue for the quarter that ended in Jan. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

BioVaxys Technology (FRA:5LB) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

BioVaxys Technology's Gross Margin % for the three months ended in Jan. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

BioVaxys Technology COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (FRA:5LB) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

BVAXF:USA BIOV:Canada

Address

595 Howe Street, Suite 303, Vancouver, BC, CAN, V6C 2T5

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

BioVaxys Technology Headlines

No Headlines